232 related articles for article (PubMed ID: 28555643)
21. Endogenous Multiple Exon Skipping and Back-Splicing at the DMD Mutation Hotspot.
Suzuki H; Aoki Y; Kameyama T; Saito T; Masuda S; Tanihata J; Nagata T; Mayeda A; Takeda S; Tsukahara T
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754374
[TBL] [Abstract][Full Text] [Related]
22. Efficient Skipping of Single Exon Duplications in DMD Patient-Derived Cell Lines Using an Antisense Oligonucleotide Approach.
Wein N; Vulin A; Findlay AR; Gumienny F; Huang N; Wilton SD; Flanigan KM
J Neuromuscul Dis; 2017; 4(3):199-207. PubMed ID: 28869484
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish.
Berger J; Berger S; Jacoby AS; Wilton SD; Currie PD
J Cell Mol Med; 2011 Dec; 15(12):2643-51. PubMed ID: 21251213
[TBL] [Abstract][Full Text] [Related]
24. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.
Charleston JS; Schnell FJ; Dworzak J; Donoghue C; Lewis S; Chen L; Young GD; Milici AJ; Voss J; DeAlwis U; Wentworth B; Rodino-Klapac LR; Sahenk Z; Frank D; Mendell JR
Neurology; 2018 Jun; 90(24):e2146-e2154. PubMed ID: 29752304
[TBL] [Abstract][Full Text] [Related]
25. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
Takeshima Y
Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
[TBL] [Abstract][Full Text] [Related]
26. Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.
O'Leary DA; Sharif O; Anderson P; Tu B; Welch G; Zhou Y; Caldwell JS; Engels IH; Brinker A
PLoS One; 2009 Dec; 4(12):e8348. PubMed ID: 20020055
[TBL] [Abstract][Full Text] [Related]
27. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
28. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
Moulton HM; Moulton JD
Biochim Biophys Acta; 2010 Dec; 1798(12):2296-303. PubMed ID: 20170628
[TBL] [Abstract][Full Text] [Related]
29. Categorization of 77 dystrophin exons into 5 groups by a decision tree using indexes of splicing regulatory factors as decision markers.
Malueka RG; Takaoka Y; Yagi M; Awano H; Lee T; Dwianingsih EK; Nishida A; Takeshima Y; Matsuo M
BMC Genet; 2012 Mar; 13():23. PubMed ID: 22462762
[TBL] [Abstract][Full Text] [Related]
30. De novo revertant fiber formation and therapy testing in a 3D culture model of Duchenne muscular dystrophy skeletal muscle.
Ebrahimi M; Lad H; Fusto A; Tiper Y; Datye A; Nguyen CT; Jacques E; Moyle LA; Nguyen T; Musgrave B; Chávez-Madero C; Bigot A; Chen C; Turner S; Stewart BA; Pegoraro E; Vitiello L; Gilbert PM
Acta Biomater; 2021 Sep; 132():227-244. PubMed ID: 34048976
[TBL] [Abstract][Full Text] [Related]
31. A novel human muscle cell model of Duchenne muscular dystrophy created by CRISPR/Cas9 and evaluation of antisense-mediated exon skipping.
Shimo T; Hosoki K; Nakatsuji Y; Yokota T; Obika S
J Hum Genet; 2018 Mar; 63(3):365-375. PubMed ID: 29339778
[TBL] [Abstract][Full Text] [Related]
32. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
33. In silico screening based on predictive algorithms as a design tool for exon skipping oligonucleotides in Duchenne muscular dystrophy.
Echigoya Y; Mouly V; Garcia L; Yokota T; Duddy W
PLoS One; 2015; 10(3):e0120058. PubMed ID: 25816009
[TBL] [Abstract][Full Text] [Related]
34. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
35. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
36. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
37. Efficient exon skipping by base-editor-mediated abrogation of exonic splicing enhancers.
Qiu H; Li G; Yuan J; Yang D; Ma Y; Wang F; Dai Y; Chang X
Cell Rep; 2023 Nov; 42(11):113340. PubMed ID: 37906593
[TBL] [Abstract][Full Text] [Related]
38. [Molecular therapies for Duchenne muscular dystrophy].
Takeshima Y
No To Hattatsu; 2016 Jul; 48(4):241-6. PubMed ID: 30010301
[TBL] [Abstract][Full Text] [Related]
39. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
[TBL] [Abstract][Full Text] [Related]
40. Moving towards successful exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A
J Hum Genet; 2017 Oct; 62(10):871-876. PubMed ID: 28566768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
